Accordingly, knockdown of FOXM1 or its downstream targets increases the sensitivity to standard chemotherapy in many human cancers, including colorectal [8, 15], gastric [18], lung [19], ovarian cancer [20], retinoblastoma [14], and nasopharyngeal carcinoma [21]. The gene discussed is FOXM1; the disease is ovarian carcinoma.